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BRCA1 Is Required for Maintenance of Phospho-Chk1 and G2/M
Arrest during DNA Cross-Link Repair in DT40 Cells
Margarethe Draga,a,d Elizabeth B. Madgett,b Cassandra J. Vandenberg,b* David du Plessis,b Aisling Kaufmann,a Petra Werler,c
Prasun Chakraborty,a Noel F. Lowndes,c Kevin Hioma,b
Division of Cancer Research, Medical Research Institute, Jacqui Wood Cancer Centre, Ninewells Hospital and Medical School, Dundee, Scotlanda; MRC Laboratory of
Molecular Biology, Cambridge Biomedical Campus, Cambridge, United Kingdomb; Genome Stability Laboratory, Centre for Chromosome Biology, School of Natural
Science, National University of Ireland, Galway, Irelandc; Institute of Anatomy II, Department of Vertebrate Embryology, University of Cologne, Cologne, Germanyd
The Fanconi anemia DNA repair pathway is pivotal for the efficient repair of DNA interstrand cross-links. Here, we show that
FA-defective (Fancc) DT40 cells arrest in G2 phase following cross-link damage and trigger apoptosis. Strikingly, cell death was
reduced in Fancc cells by additional deletion of the BRCA1 tumor suppressor, resulting in elevated clonogenic survival. In-
creased resistance to cross-link damage was not due to loss of toxic BRCA1-mediated homologous recombination but rather
through the loss of a G2 checkpoint. This proapoptotic role also required the BRCA1-A complex member ABRAXAS (FAM175A).
Finally, we show that BRCA1 promotes G2 arrest and cell death by prolonging phosphorylation of Chk1 on serine 345 after DNA
damage to sustain arrest. Our data imply that DNA-induced cross-link death in cells defective in the FA pathway is dependent on
the ability of BRCA1 to prolong cell cycle arrest in G2 phase.
The Fanconi anemia (FA) repair pathway is dedicated to therepair of replication blocking lesions, such as interstrand DNA
cross-links (ICL) and DNA-protein cross-links, which pose a ma-
jor threat to the maintenance of genomic stability. Defects in any
of 17 FA genes in patients confer the hematological disease Fan-
coni anemia. Characteristically, defects in any of these genes ren-
der patients’ cells exquisitely sensitive to DNA cross-linking
agents such as mitomycin C, cis-diamminedichloridoplatinum
(II) (cisplatin), diepoxybutane (1), and reactive aldehydes that
cause DNA-protein cross-links (2, 3). The FA pathway is also con-
served in organisms as diverse as dictyostelium, nematodes, am-
phibians, birds, and mammals.
Genetic and biochemical evidence suggests that DNA cross-
links represent a strong physical block to replicative polymerases;
however, the molecular pathway whereby DNA cross-links are
removed and the chromosomes restored by the FA pathway is only
partially understood. Eight FA proteins (FANCA, -B, -C, -E, -F,
-G, -L, and -M) form a core complex that is recruited to sites of
ICL damage, where it ubiquitylates FANCD2 and FANCI (4–6).
Although not fully understood, the recruitment of FA proteins to
ICLs or to DNA-protein cross-links (DPC) signals for the recruit-
ment of nucleases that incise and unhook DNA cross-links, en-
abling replication across these noncoding lesions using a transle-
sion polymerase (7, 8). The process is completed with the repair of
any resultant DNA breaks through homologous recombination
(HR).
Failure to repair DNA cross-link damage in cells defective in
the FA pathway results in greatly elevated cell death. Although cell
death may arise through failure to complete cell division leading
to mitotic catastrophe, a significant proportion occurs through
apoptosis following prolonged cell cycle arrest in G2 phase. The
genetic determinants regulating this proapoptotic response to ICL
and DPC damage are poorly understood.
The BRCA1 tumor suppressor protein is known to play a role
in DNA cross-link repair in a variety of cell types (4), primarily
through its role in promoting HR. However, Bunting et al. re-
cently proposed that BRCA1 has another role in the FA pathway,
upstream of its function in HR (9), to facilitate retention of
FANCD2 at sites of cross-link repair by influencing local chroma-
tin structure (4, 9, 10).
In addition to its role in promoting repair of DNA damage by
HR, BRCA1 has been shown to play a role in ionizing radiation
(IR)-induced cell cycle checkpoints at S and G2 phases (11).
Yarden et al. reported that expression of BRCA1 also restored an
IR-induced G2 arrest to the BRCA1-defective cancer cell line
HCC1937 (12). Moreover, the restoration of G2/M checkpoint
function correlated with increased activation of Chk1 for the
phosphorylation of the cell cycle regulator Cdc25C. In contrast,
the p53-dependent G1-S cell cycle checkpoint is intact in BRCA1-
defective cells (13).
We wanted to understand how BRCA1 might also contribute
to cell cycle checkpoint arrest and viability in the FA pathway. To
do this, we used the genetically tractable avian cell line DT40,
which has previously been established as a good model for FA
mediated cross-link repair (10, 14). We report that the lethal effect
of cisplatin treatment in Fancc mutant DT40 cells is ameliorated
by defects in BRCA1, BARD1, and ABRAXAS (ABRA1). More-
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over, we found that increased survival is not linked to repair of
lesions by homologous recombination but arises through a failure
to maintain cell cycle arrest in G2 phase. Together, our data sup-
port an important role for BRCA1 to regulate the proliferation of
vertebrate cells containing DNA damage and promote genome
stability.
MATERIALS AND METHODS
Cell culture. DT40 chicken cells were propagated in standard RPMI me-
dium-supplemented medium at 37°C and 5% CO2. Where indicated, 500
M indole-3-acetic acid was used to deplete BRCA1-DEG protein. The
generation of Abra1/ and Fancc Abra1/ DT40 mutant cells was
described by D. du Plessis in 2012 (unpublished data).
Antibodies. Antibodies against Chk1 (Sc-8408), phosphoserine
345Chk1 (catalog no. 2348), and BRCA1 (Ab-1) were purchased from
Santa Cruz Biotech, Cell Signaling, and Calbiochem, respectively.
Clonogenic survival assay. Cells were incubated for 1 h at 37°C with
medium containing 1 to 40 M cisplatin as indicated. Cells were washed
and suspended in fresh medium, and serial dilutions were plated in me-
dium containing 1% methylcellulose. Where indicated, 2 mM caffeine
(Sigma) was included for 1 h prior to addition of cisplatin. Colonies were
counted after 8 to 10 days of incubation.
Cell cycle analysis. Cells were treated with cisplatin as described
above. At different times, the cells were pulsed with 20 M bromodeoxy-
uridine (BrdU; Sigma) for 20 min, washed twice with phosphate-buffered
saline (PBS), and fixed overnight in 70% ethanol at 20°C. We stained
cells with antibody to BrdU conjugated to fluorescein isothiocyanate as
previously described (14) and analyzed by using a FACScan cytometer
(Becton Dickinson).
Mitotic index. A 1 M concentration of nocodazole (Sigma) was
added to cells 15 to 16 h after treatment with cisplatin, followed by incu-
bation for 6 to 7 h. The cells were washed in PBS and fixed overnight in
70% ethanol at 20°C. The cells were stained with rabbit polyclonal an-
tibody to histone H3 (phospho-S10; AbCam) and then with antibody to
rabbit conjugated to fluorescein isothiocyanate (Southern Biotechnol-
ogy) for 30 min, resuspended in PBS containing 25 g of propidium
iodide/ml, and analyzed by using a FACScan cytometer (Becton Dickin-
son).
Comet assay. A modification of alkaline comet assay was performed.
Cells were harvested by centrifugation (800 rpm) and kept on ice. Ap-
proximately 9 104 cells were resuspended in 30 l of PBS and 300 l of
low-melting-point agarose (LMA; 0.5%) and then placed on a slide per-
colated with agarose. Cells were lysed using lysis buffer (2.5 mM NaCl, 100
mM EDTA, 10% Tris [pH 10]; 1% Triton and 10% dimethyl sulfoxide
were added fresh) for 1 to 2 h at 4°C. Slides were preincubated in alkaline
solution for 30 min to 1 h and electrophoresed for 30 min at 21 V (0.86
V/cm) and 300 mA. Slides were neutralized, dried, stained with SYBR
green, and analyzed using a fluorescence microscope (LSM 500; Zeiss).
Tail moment was measured using Comet Score software. 100 cells per
slide were evaluated, and the mean of tail moment (TM) was determined.
Elutriation. A total of 3 108 DT40 cells were collected by centrifu-
gation and resuspended in 50 ml of PBS plus 1% fetal bovine serum and
then drawn into a standard (4-ml) chamber at 2,500 rpm in a Beckman
JE-5.0 centrifugal elutriation rotor at a flow rate of 15 ml/min. The cells in
G1 were harvested by altering the flow rate to 21 ml/min. A 150-ml frac-
tion was collected, and the cells were harvested by centrifugation and then
resuspended in fresh RPMI medium.
MTS assay. DT40 cells were treated with different concentrations of
cisplatin. In one experiment, the cisplatin was washed off after 1 h. Cell
lines were plated into 96-well plates at a density of 15,000 cells per well.
The plates were put in an incubator for 48 h, and then 20l of CellTiter 96
Aqueous One solution reagent (Promega) was added to each well, fol-
lowed by incubation for 4 h at 37°C and 5% CO2. The absorbance was
measured at 490 nm.
Chromosome break analysis. Chromosome breaks were analyzed by
metaphase spread from cells incubated with or without treatment with 1
M cisplatin for 1 h. After 15 h, colcemid was added for 1.5 h, and the cells
were harvested and then incubated with 75 mM KCl for 25 min. The cells
were fixed with methanol-acetic acid (3:1) four times and then stored at
20°C. Cells were dropped onto slides and stained with DAPI (4=,6=-
diamidino-2-phenylindole). A total of 50 metaphases were scored for each
treatment. Scoring was restricted to chicken macrochromosomes only.
RESULTS
The lethal effect of ICLdamage inFancc cells is ameliorated by
defects in BRCA1/BARD1. To investigate the function of BRCA1
in DNA cross-link repair, we compared the cisplatin sensitivity of
Fancc, Brca1/, and Fancc Brca1/ double-mutant DT40
cells in clonogenic and MTS survival assays. We previously re-
ported that, like cells from FA patients, Fancc and Brip1/ (also
called Fancj/) mutant DT40 cells exhibit acute sensitivity to
cisplatin-induced DNA damage (14). We confirmed this again for
Fancc mutant cells (Fig. 1A). In marked contrast, Brca1/ mu-
tant DT40 were minimally sensitive to treatment with doses of
cisplatin up to 2.5 M in a clonogenic survival assay and more
resistant than wild-type cells to cisplatin in a MTS assay (Fig. 1A;
see Fig. S1 in the supplemental material) (14). This result was
surprising, since other HR-defective DT40 mutants, such as
Xrcc2/ cells, are sensitive to ICL damage (10, 15). Nevertheless,
we confirmed our findings using multiple clones from two inde-
pendently constructed BRCA1/ mutant cell lines (data not
shown).
The lack of cisplatin sensitivity observed in BRCA1/mutant
DT40 contrasts with the cisplatin sensitivity reported for a range
of BRCA1-defective mammalian cell lines (16–18). We can think
of several reasons why this might be the case. First, BRCA1 might
function differently in the repair of cisplatin-induced damage in
avian and mammalian cells. Second, differences might reflect the
fact that DT40 is a transformed B-cell line compared to most
cancer cell lines, which are of epithelial origin. Finally, the sensi-
tivity of cells to DNA damage is profoundly affected by genetic
background in different cell lines. For example, whereas some
BRCA2 defective human tumors exhibit sensitivity to treatment
with DNA cross-linking agents, cells from mice specifically mu-
tated in BRCA2 are largely insensitive to this damage (19). Like-
wise, the profound sensitivity of BRCA1-defective cells to PARP
inhibitors is diminished or lost in cells that also carry a defect in
53BP1.
We previously reported that our Brca1/ mutant cells are
impaired in homologous recombination (10, 14, 20). To confirm
that this cell line exhibits another important phenotype character-
istic of mammalian cells defective in BRCA1, we tested its sensi-
tivity to the PARP inhibitor olaparib. Consistent with the behavior
of cells from BRCA1-defective patients and cells fromBrca111/11
mice, our Brca1/ DT40 mutant was profoundly sensitive to
treatment with olaparib. Moreover, sensitivity to olaparib was
corrected by expression of a BRCA1 transgene (see Fig. S1 in the
supplemental material). Furthermore, as in mammals, sensitivity
to olaparib was also partially reversed in Brca1/ mutant DT40
with an additional defect in 53BP1 (21, 22). From this we infer that
Brca1/DT40 cells share fundamental characteristics with mam-
malian cell lines defective in BRCA1.
Perhaps more surprising than the insensitivity of Brca1/
DT40 to cisplatin treatment was the decreased cisplatin sensitivity
observed in Fancc Brca1/ double-mutant cells. These mutant
Draga et al.
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FIG 1 Defects in BRCA1 ameliorate the sensitivity ofFanccDT40 cells to cisplatin treatment. (A and B) Graphs showing clonogenic survival curves for indicated DT40
mutant cells after treatment with different concentrations of cisplatin. Fancc Brca1/ and Fancc Bard1/ are less sensitive to treatment with low doses of cisplatin
compared to Fancc cells. (A) Fifty percent inhibitory concentration values (IC50): wild-type cells, 3.5 M; Fancc
 cells, 0.8 M; Brca1/ cells, 3.4 M; and Fancc
Brca1/ cells, 3.8M. (B) IC50 values: wild-type cells, 3.2M; Fancc
 cells, 0.47M; Bard1/ cells, 1.1M; and Fancc Bard1/ cells, 0.7M. The data presented
are means from three experiments; error bars indicate one standard deviation. (C) A comet assay showed the increased tail moment and therefore the persistence of DNA
breaks in wild-type and mutant DT40 cells, as indicated. Cells were treated with 1M cisplatin for 1 h, allowed to recover in fresh medium for 15 h, and then analyzed
by alkaline comet assay. Tail moments (TM) were calculated for100 comets from each sample, and the percentage of cells showing a specific TM was plotted. (D)
Mutant cells were treated with 1M cisplatin for 1 h, allowed to recover in fresh medium for 12 h, and then stained with primary antibody againstH2AX and secondary
antibody conjugated to fluorescein isothiocyanate. H2AX was quantified by fluorescence-activated cell sorting (FACS), where the FL1 channel corresponds to
fluorescein. A green histogram represents untreated cells, and a white histogram represents cells treated with 1M cisplatin. (E) Quantification of H2AX staining in
panel D measured in arbitrary units. Further information is contained in Fig. S1 and S3 in the supplemental material.
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cells exhibited normal survival after treatment with 2.5M cispla-
tin, a dose at which only 5 to 10% Fancc cells survive (Fig. 1A and
B). This suggested that loss of BRCA1 function abrogated the toxic
effect of 2.5 M cisplatin in Fancc cells. It is noteworthy that the
ameliorating affect of BRCA1 defects in Fancc cells was dimin-
ished after treatment with higher concentrations of cisplatin (up
to 40 M), where the burden of DNA lesions is likely sufficient to
cause cell death through mitotic catastrophe (see Fig. S1 in the
supplemental material).
In vivo, BRCA1 functions as a heterodimeric complex with its
interacting partner BARD1 (23). Therefore, we next measured
clonogenic survival of Bard1/ and Fancc Bard1/ mutant
cells treated with cisplatin (Fig. 1B). Like Brca1/ mutant cells,
Bard1/ mutant cells were much less sensitive to cisplatin treat-
ment than were Fancc cells. Moreover, the survival was markedly
improved in FanccBard1/ cells compared to the Fancc single
mutant. Hence, the loss of functional BARD1, like the loss of
BRCA1, ameliorated the toxic effects of cisplatin in FANCC-defi-
cient cells. However, we note that Fancc Bard1/ mutant cells
remained slightly more sensitive to cisplatin than the Fancc
Brca1/ compared to a wild-type control.
It was previously reported that inhibition of nonhomologous
end joining (NHEJ) suppressed ICL sensitivity in Caenorhabditis
elegans mutants defective in the FA pathway, and also in FA-de-
fective DT40 and mammalian cell lines (24, 25). Inhibition of
NHEJ in these cells also reduced DNA cross-link-induced chro-
mosome breakage and promoted HR. It was inferred that double-
strand breaks (DSBs) generated in the absence of a functional FA
pathway are diverted into abortive and toxic repair by NHEJ. In-
hibition of NHEJ restored repair fidelity to these cells by permit-
ting more accurate processing of DSB intermediates through HR,
resulting in increased cell survival.
We next investigated whether defects in BRCA1 could similarly
restore efficient and accurate repair of ICL damage in Fanccmu-
tant cells. To do this, we measured the level of unrepaired breaks
in cisplatin-treated cells, using a comet assay (Fig. 1C). We found
that treatment with 1 M cisplatin for 1 h produced an increased
comet tail moment in Fancc, Brca1/, Bard1/, Fancc
Brca1/, and Fancc Bard1 mutant cells 15 h later compared to a
wild-type control. This indicated the persistence of unrepaired
DNA damage (Fig. 1C). The distribution of cells with increased
tail moment was slightly different inFanccBrca1/mutant cells
compared to Fanccmutant cells, with the latter comprising more
cells with a tail moment of 10. Mutant cells also exhibited in-
creased H2AX staining compared to wild-type cells (Fig. 1D and
E), indicating the persistence of unrepaired DNA lesions. Hence,
the improved survival afforded to Fancc cells by defects in
BRCA1 or BARD1 could not be explained by enhanced repair of
ICL-induced DNA breaks.
Defects in BRCA1/BARD1 abrogate ICL-induced cell cycle
arrest in Fancc cells. Increased resistance to cisplatin induced-
damage in Fancc Brca1/ and Fancc Bard1/ cells was not
mediated through enhanced repair efficiency. Therefore, we hy-
pothesized that these mutant cells might have an increased toler-
ance to unrepaired DNA damage. Agents such as cisplatin and
mitomycin C are known to cause FA-defective cells to undergo
prolonged arrest in G2 phase, with a concomitant increase in
apoptotic cell death (26, 27). We next investigated the progression
of different mutant cells through the cell cycle after cisplatin treat-
ment. Cells were treated with cisplatin for 1 h, and the proportion
of cells accumulating in G2 phase was measured over time by
staining with propidium iodide (Fig. 2A and B). We also measured
the accumulation of cells in mitosis (mitotic index) by staining for
phospho-histone H3 after addition of nocodazole (Fig. 2C).
Lastly, we measured apoptotic cell death by staining for annexin V
(Fig. 2D) and by quantifying sub-G1 cells stained with propidium
iodide (Fig. 2B).
As expected, Fancc mutant DT40 exhibited a profound cell
cycle delay in response to cisplatin treatment compared to wild-
type cells, with ca. 70% of cells accumulating in G2 phase (4C)
after 21 h (Fig. 2A). This contrasted markedly with wild-type cells
that exhibited a slight increase in G2 population approximately 12
to 15 h after cisplatin treatment but returned to starting levels at 21
h (Fig. 2A and B), with little or no increase in apoptosis (Fig. 2D).
These experiments were performed on an asynchronous pop-
ulation of cycling cells. However, different mutant cell lines may
exhibit minor differences in cell cycle progression (see Fig. S2 in
the supplemental material). To confirm that differences in transit
into mitosis after cisplatin treatment was caused by cell cycle ar-
rest/delay and not by inherent differences in cell cycle progression
between wild-type and mutant cells, we measured the accumula-
tion of mitotic cells in the presence of the mitotic spindle poison,
nocodazole. This permitted us to quantify the accumulation of
cells in mitosis several hours after treatment with the DNA-dam-
aging agent and calculate the proportion of the cell population in
mitosis after a specific time. Treatment of Fancc cells with cispla-
tin caused a clear decrease in mitotic index compared to wild-type
control, indicating impaired transit of cells into M phase. This is
consistent with the execution of a DNA-damage-induced check-
point at G2 phase (Fig. 2C). Furthermore, arrest was accompanied
by a marked increase in apoptotic cell death, presumably through
the failure of arrested cells to repair DNA damage (Fig. 2B to D).
Despite significant levels of unrepaired DNA breaks, cisplatin-
treated Brca1/ and Bard1/ cells progressed through the cell
division cycle and into mitosis with very little delay in G2. We
measured only a small increase in apoptotic cell death for
Brca1/ cells (Fig. 2B and D; see Fig. S1 in the supplemental
material). The lack of G2 arrest was even more apparent when
comparing Fancc cells with Fancc Brca1/ and Fancc
Bard1/ double mutants. Whereas 70 to 80% Fancc cells accu-
mulated in G2 phase 21 h after cisplatin treatment, only 40 to 45%
of Fancc Brca1/ and Fancc Bard1/ mutants were in G2
(Fig. 2A; see Fig. S1 in the supplemental material). Moreover, we
measured no ICL-induced decrease in mitotic index in Fancc
Brca1/ mutant cells, a finding consistent with their unhindered
progression into mitosis (Fig. 2C). The failure of cisplatin-treated
Fancc Brca1/ cells to arrest in G2 was accompanied by a sig-
nificant decrease in apoptotic cell death compared to Fancc cells
(Fig. 2B and D). The proliferation of cells with persistent unre-
paired DNA damage is consistent with the increased levels of
chromosome abnormalities measured in DT40 cells with defects
in BRCA1 and FANCC (see Fig. S3 in the supplemental material)
(10, 15). Since entry into mitosis with unrepaired DNA damage is
characteristic of a defective cell cycle checkpoint, we reasoned that
BRCA1 and BARD1 might be required to promote an ICL-in-
duced G2/M checkpoint in the FA pathway.
Defects in ABRAXAS but not BRIP1 abrogate accumula-
tion of cells in G2. Although BRCA1 has been implicated in a
G2/M checkpoint induced by ionizing radiation, its mechanism of
action is unclear (11). However, BRCA1 is known to interact in a
Draga et al.
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cell cycle-dependent manner with the ABRAXAS (Fam175A),
BRIP1 (FANCJ), and CtIP proteins, forming the BRCA1-A,
BRCA1-B, and BRCA1-C complexes, respectively (28–30). Al-
though CtIP plays an important role in the resection of DSB to
promote homologous recombination, BRIP1 and ABRAXAS have
been implicated in ionizing radiation (IR)-induced checkpoint
function (31–35). We hypothesized that ABRAXAS and/or BRIP1
proteins might contribute to cell cycle arrest in cisplatin-treated
FA cells.
We previously reported that Fancc Brip1/ double mutant
cells are more sensitive to ICL damage than either Brip1/ or
Fancc single mutants (14). Accordingly, we found that treatment
of Fancc Brip1/ cells with cisplatin caused an even more pro-
found decrease in mitotic index than observed in Fancc mutant
cells. We concluded that the G2 checkpoint was functioning nor-
mally in these cells (Fig. 3A). In contrast, Fancc Abra1/ mu-
tant cells were much less sensitive to cisplatin-induced damage
than Fancc cells (Fig. 3B). Moreover, neither Abra1/ nor
Fancc Abra1/ mutant cell lines exhibited prolonged accumu-
lation in G2 phase after exposure to 1 M cisplatin (Fig. 3C).
Consistent with this, we measured little decrease in mitotic index
in Abra1/ or Fancc Abra1/ cells treated with cisplatin (Fig.
3D). This again indicated a failure to arrest in G2 despite elevated
levels of unrepaired DNA breaks (Fig. 3E). Reintroduction of
ABRAXAS into Fancc Abra1/ cells restored cisplatin-induced
decrease in mitotic index in these cells, indicating a functional cell
FIG 2 Fancc mutant cells, but not Brca1/ or Fancc Brca1/ cells, arrest with 4C DNA content and undergo apoptotic cell death after treatment with
cisplatin. (A and B) Wild-type and mutant cells were damaged by 1 M cisplatin, pulse-labeled with BrdU, and harvested at the times indicated. Cells were
analyzed for BrdU incorporation and propidium iodide staining by FACS to determine the DNA content. The percentages of cells with near 4C DNA content and
therefore in G2/M phase (green boxes) of the cell cycle are shown at different times after DNA damage treatment. (C) Fancc
 mutant cells, but not Brca1/ or
Fancc Brca1/ cells, arrest prior to entering mitosis after treatment with cisplatin. The mitotic index of cells treated with 1M cisplatin is shown. Nocodazole
was added 15 h after damage treatment to trap cells entering mitosis. Mitotic cells were quantified 24 h after treatment by staining for pSer-H3 and measured by
FACS. The mitotic index is calculated as the ratio of treated to untreated cells staining positive for pSer-H3. (D) Loss of BRCA1 function reduces apoptotic cell
death in Fanccmutant cells. The percentage of cells that stained for annexin V, 22 h after treatment 1M cisplatin, was used as a measurement of apoptosis. The
data shown in panels A, C, and E show the means from three experiments; error bars indicate the standard deviations. See also Fig. S1 in the supplemental
material.
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cycle arrest. We concluded that, like defects in BRCA1/BARD1,
the loss of ABRAXAS function is linked to impaired cell cycle
arrest in Fancc mutant cells treated with cisplatin. It is of partic-
ular note that, whereas BRCA1 mutant cells are impaired for ho-
mologous recombination, human and DT40 cells defective in
ABRAXAS are not HR defective (36). This indicates that the ICL-
induced checkpoint might be genetically separable from HR.
BRCA1 andABRAXAS are required for themaintenance but
not the initiation of G2 arrest in FA cells. DNA damage-induced
checkpoints are established through the activity of the checkpoint
kinases ATM and ATR. Treatment with caffeine, which inhibits
the action of these kinases, has previously been shown to modulate
G2 accumulation in response to X-rays (37). Therefore, we exam-
ined the effect of inhibiting these kinases on ICL-induced G2 arrest
in Fancc cells. We treated wild-type and mutant cells with 1 M
cisplatin for 1 h in the presence or absence of caffeine to inhibit
ATM and ATR and measured clonogenic survival and the mitotic
index. We found that inclusion of caffeine markedly improved the
survival of Fancc cells treated with 0.5 to 2 M cisplatin (Fig. 4A
and B). Survival in caffeine-treated Fancc cells was almost iden-
tical to that of FanccBard1/mutant cells. The mitotic index of
these cells was also similar to the wild type, an observation consis-
tent with a progression into mitosis without delay (Fig. 4C). Im-
portantly, caffeine had little additional impact on either the sur-
vival or mitotic index in Fancc Bard1/ cells. We observed a
similar defect in cell cycle arrest upon treatment of Fancc cells
with specific inhibitors of ATM and ATR, i.e., KU55933 and ETP
46464, respectively (see Fig. S4 in the supplemental material). We
infer that BRCA1/BARD1 probably functions in a pathway in-
volving ATM and ATR kinases to promote ICL-induced G2 arrest.
A key effector in the G2/M checkpoint is the CHK1 kinase.
CHK1 functions downstream of ATR in the checkpoint pathway
and is activated upon DNA damage by its phosphorylation on
serine 345. It has been proposed that BRCA1 is required to activate
CHK1 in response to IR-induced DNA damage (12).
We next investigated whether BRCA1 was also required for the
FIG 3 Loss of ABRAXAS but not BRIP1 abrogates G2/M arrest in FANCC-defective cells. (A) Mitotic index of mutant cells treated and not treated with 1 M
cisplatin and stained for pSer-H. (B) Clonogenic survival curves for indicated DT40 mutant cells after treatment with different concentrations of cisplatin.Fancc
Abra/mutants are less sensitive to treatment with low doses of cisplatin than Fancc cells. (C) Fancc cells, but not Abra1/ or FanccAbra1/ cells, arrest
in G2/M with near 4C DNA content after cisplatin treatment. DNA content was quantified by using FACS after incorporation of BrdU into cells and after staining
with propidium iodide. The percentage of cells with 4C content and therefore in G2/M phase are shown. (D) Mitotic index of cells treated or not treated with 5
M cisplatin. The percentage of cells positive for pSer-H3 is shown. The experiments from panels C and D were performed at the same time as those depicted in
Fig. 2A and C. The wild-type control in the latter experiments can be used for comparison. (E) A comet assay of mutant cells (as indicated) shows the persistence
of DNA strand breaks 15 h after treatment with 1 M cisplatin. Tail moments were calculated for100 comets and are shown as a percentage in the total cell
population. The data shown in panels A to D are the means from three experiments; error bars indicate the standard deviations.
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activation of CHK1 in response to DNA cross-link damage, or
whether the kinetics of CHK1 activation was altered in these cells.
To do this, we isolated synchronous populations of different mu-
tant cells in G1 phase using centrifugal elutriation, treated them
with 1 M cisplatin for 1 h and measured the activation of CHK1
over time by Western blotting using antibody against
pCHK1(ser345) (Fig. 5A). As expected, wild-type cells had ele-
vated levels of pCHK1(ser345) 12 h after cisplatin treatment,
which diminished by 15 h. In Fancc cells, CHK1 was also acti-
vated but persisted at 18 h, reflecting their failure to repair DNA
damage. Interestingly, pCHK1(ser345) was also observed 12 h af-
ter cisplatin treatment inBrca1/ andFanccBrca1/ cells, but,
unlike Fancc mutant cells, this was largely diminished after 18 h.
This suggested that initial activation of CHK1 through phosphor-
ylation of serine 345 was not defective in Brca1/ and Fancc
Brca1/ cells, and it did not explain the failure of these mutant
cells to arrest in G2 phase. Instead, the progression of Brca1
/
and Fancc Brca1/ cells into mitosis seemed to correlate with a
failure to maintain pCHK1(ser345).
To investigate the contribution of BRCA1 to the maintenance
of pCHK1(ser345), we used the auxin-inducible degron system,
generating BRCA1 protein that could be rapidly depleted upon
addition of the plant auxin indole-3-acetic acid (IAA) (38). We
fused BRCA1 to an auxin-inducible degron (BRCA1-DEG) and
introduced it as a transgene into Fancc Brca1/ mutant DT40
cells. We next confirmed that 90% BRCA1-DEG protein was
depleted in cells 15 min after addition of 500M IAA (Fig. 5B). To
measure the consequences of rapid BRCA1 depletion, we treated a
synchronized G1 culture of Fancc
 Brca1/ cells expressing the
BRCA1-DEG transgene with cisplatin for 1 h in the presence or
absence of IAA and monitored their progression through the cell
cycle as described previously (Fig. 5C). We confirmed that, in the
absence of IAA, Fancc Brca1/ expressing BRCA1-DEG be-
haved as Fancc mutant cells, arresting in G2 phase 15 h after
cisplatin treatment (Fig. 5D and E). These cells also had elevated
levels of pCHK1(ser345) at 15 h, which persisted 22 h posttreat-
ment (Fig. 5F, lanes i, k, and n), confirming that the BRCA1-DEG
transgene was functional.
We then repeated the experiment, including 500 M IAA in
the medium throughout, to deplete BRCA1-DEG. As expected,
depletion of BRCA1-DEG resulted in the failure of cells to accu-
mulate in G2 with no observed decrease in mitotic index, mirror-
ing the behavior of Fancc Brca1/ mutant cells (Fig. 5D, col-
umn e). Moreover, while the level of pCHK1(ser345) in these cells
was elevated 15 h after cisplatin treatment, it was significantly
diminished after 18 to 21 h (Fig. 5F, lanes j, l, and o), confirming
impaired cell cycle arrest in these cells. It was again of note that
constitutive depletion of BRCA1 throughout the experiment did
not impair the initial activation of CHK1 by phosphorylation of
FIG 4 Caffeine treatment improves survival in FanccDT40 mutant cells treated with cisplatin. (A and B) Clonogenic survival assays were performed for mutant
cells treated with different concentrations of cisplatin and in the presence or absence of 2 mM caffeine. The inclusion of 2 mM caffeine in the media improves
survival in Fancc cells treated with different concentrations of cisplatin. (C) Mitotic index of cells treated and not treated with 5 M cisplatin with or without
2 mM caffeine. The percentage of cells positive for pSer-H3 is shown. Caffeine improves cell cycle progression into mitosis in Fancc cells. The data presented are
the mean of three experiments; error bars indicate one standard deviation. See also Fig. S4 in the supplemental material.
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serine 345, but the persistence of pCHK1(ser345) was affected at
later time points.
To determine whether loss of BRCA1 function is directly
linked to exit from cell cycle arrest in G2, we treated a G1 popula-
tion of FanccBrca1/ cells expressing BRCA1-DEG with cispla-
tin for 1 h and incubated them for a further 22 h to permit the cells
sufficient time to arrest in G2 (Fig. 5E). During this incubation,
we added 500 M IAA to different samples at different time
points—15, 18, and 21 h—in order to deplete BRCA1. The cells
were harvested at 22 h, and the mitotic index was determined.
We found that depletion of BRCA1 resulted in a clear time-
dependent increase in mitotic index, with most cells progress-
ing into mitosis within 6 h after BRCA1 depletion (Fig. 5D,
compare columns a to d). Moreover, G2 exit coincided with a
rapid and significant reduction in pCHK1(ser345) (Fig. 5F,
compare lanes l, m, and p). This contrasted sharply with the cell
cycle arrest and persistence of pCHK1(ser345) in cells express-
ing functional BRCA1.
We conclude that BRCA1, BARD1, and ABRAXAS help
maintain cell cycle arrest/delay in FA cells treated with cisplatin
and that this requirement persists many hours after the initial
exposure to DNA damage. This failure to arrest correlates with
improved survival of FA cells to low levels of DNA cross-link
damage.
DISCUSSION
BRCA1 has been implicated in the repair of interstrand DNA
cross-links by promoting homology-dependent repair of DNA
breaks in the FA pathway (4, 10). We present evidence that, in
DT40, BRCA1/BARD1 may play another important role, by help-
ing to maintain G2/M phase cell cycle arrest in FA cells with unre-
paired DNA damage.
We report that cell cycle arrest and subsequent apoptotic cell
death, which occurs in FA-defective DT40 cells after treatment
with DNA cross-linking agents, is lost in BRCA1-deficient cells.
Instead, cisplatin-treated FA cells lacking functional BRCA1 tran-
sit through G2 phase and mitosis with unrepaired DNA damage,
leading to an increase in overall viability.
Our initial observation that Brca1/ DT40 cells are not very
sensitive to cisplatin-induced DNA damage is at variance with
studies in mammalian cancer cell lines. Nevertheless, we con-
firmed our observations using independently derived Brca1/
mutant cell lines (data not shown). It is possible that avian and
mammalian cells deal differently with DNA cross-link damage.
However, this is unlikely, because DT40 has previously provided
an excellent model for the FA pathway in vertebrates. Alterna-
tively, there might be differences in the DNA damage response
(DDR) between lymphocytes and epithelial cancer cells. Finally,
the discrepancy might reflect differences in genetic background of
these cell lines, which is known to have a profound influence on
sensitivity to DNA damage (as discussed above). Nevertheless,
despite the overlapping biological mechanisms of the FA and
BRCA1 pathways in DT40 and human cells, the clinical relevance
of these findings in cancer should be treated with caution.
That Fancc Brca1/DT40 cells are defective for the repair of
DNA cross-link damage but are minimally sensitive to 1 M cis-
platin treatment, is reconciled by our demonstration that defects
in BRCA1 impair cross-link-induced G2/M checkpoint activity.
We note that this is most apparent after relatively short exposure
(1 h) to moderate levels of cisplatin, where cell death occurs largely
through apoptosis as part of the DDR, rather than through cata-
strophic mitosis. The link between repair of DNA lesions and cell
cycle progression is critical to prevent the proliferation of cells
with unrepaired DNA damage. Our data indicate that BRCA1
plays a key role to promote DDR-mediated cell death in cells with
unrepaired cross-link damage. It is likely that the combination of
defective DSB repair and failure to promote death in BRCA1/
cells with unrepaired DNA damage accounts for the profound
increase in chromosomal aberrations observed in these cells (10).
The resolution of DNA cross-link damage is multifaceted, in-
volving interplay between several DNA repair pathways. Several
years ago, the Patel and La Volpe groups reported that suppression
of NHEJ in FA cells resulted in increased resistance to treatment
with DNA cross-linking agents. These researchers hypothesized
that the suppression of NHEJ promoted the accurate repair of
DNA breaks through HR, rather than abortive and toxic repair
that ensues when NHEJ is functional (12, 24, 25). Our data indi-
cate that the relationship between the FA pathway and BRCA1 is
different, with resistance to DNA cross-link damage promoted
through abrogation of DNA damage-induced checkpoint func-
tion, rather than interplay between potentially conflicting repair
pathways.
BRCA1 has previously been implicated in the G2/M checkpoint
in response to IR (11). A key effector in IR-induced cell cycle arrest
is the checkpoint kinase Chk1, which is activated through phos-
phorylation on serine residue 345. Yarden et al. reported that
BRCA1-defective HCC1937 cells fail to arrest in G2/M after treat-
ment with IR and that reexpression of BRCA1 in these cells re-
stored IR-induced G2 arrest with a concomitant increase in the
activation Chk1 (12). It was subsequently shown that BRCA1 con-
FIG 5 BRCA1 is required to maintain CHK1 activation in response to DNA damage. (A) CHK1 is activated through phosphorylation at serine 345 in response
to cisplatin-induced DNA damage in wild-type and mutant cell lines (as indicated). A G1 population of cells for each mutant cell line was collected by centrifugal
elutriation and treated with cisplatin for 1 h. The cells were incubated for the indicated times and analyzed for the presence of unmodified and phosphorylated
(activated) CHK1 by Western blotting. (B) BRCA1-tagged with an auxin-inducible degron sequence (BRCA1-DEG) was expressed as a transgene in Fancc
Brca1/ cells. Depletion of BRCA1-DEG with time after addition of 500 M IAA was measured by Western blotting. Approximately 90% of the BRCA1-DEG
protein was depleted within 15 min. (C) Schematic diagram depicting the experiments described in panels D and F. A 1M concentration of cisplatin was added
to FanccBrca1/ cells for 1 h at time zero, and the cells were grown for a further 22 h before harvesting them for analysis as described in panels D and F. BRCA1
was depleted in different samples of cells at 0, 15, 18, and 21 h by the addition of 500M IAA. (D) Depletion of BRCA1 correlates with impaired cell cycle arrest
and progression into mitosis. Fancc Brca1/ cells expressing a Brca1-DEG transgene arrest in G2, as indicated by a decrease in the mitotic index. Depletion of
BRCA1-DEG at 0, 15, 18, or 21 h after DNA damage results correlates with progression into mitosis as indicated by increased mitotic index. G1-synchronized
Fancc Brca1/ cells plus BRCA1-DEG cells were treated with cisplatin for 1 h and then incubated for 22 h in fresh media. Next, 500 M IAA was added to
different samples. Cells were harvested after 22 h, and the mitotic index was determined (as described above). The data presented are the means from three
experiments; error bars indicate one standard deviation. (E) Cell cycle profile of cisplatin-treated cells in panel D after the addition of IAA. Cells were fixed and
stained with propidium iodide and analyzed by FACS to determine the DNA content. (F) Phosphorylation of CHK1 at Ser345 was determined in cell populations
treated as for panel D. Loss of pCHK1 correlates with progression of cells into mitosis as determined by mitotic index (described above).
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tributes directly to the phosphorylation of Chk1 by promoting its
association with claspin (12, 39). Together, these studies indicated
a role for BRCA1 in the initiation of onset of IR-induced check-
point signaling by promoting activation of Chk1.
This is clearly not the case in DT40 treated with DNA cross-
linking agents. Fancc Brca1/ and Brca1/ mutant cells initi-
ate normal checkpoint signaling after cisplatin treatment with
concomitant increased levels of pCHK1(ser345). Instead, we
found that BRCA1 is required to prolong G2 arrest and that de-
pletion of BRCA1 coincides with rapid exit of cells from G2 and
entry into mitosis, with a significant reduction in pCHK1(ser345).
Therefore, BRCA1 is required to maintain checkpoint function
many hours after the initial exposure to DNA damage. It is cur-
rently not clear whether BRCA1 contributes directly to the main-
tenance of the pCHK1(ser345) signal or if the pCHK1(ser345)
diminishes as a consequence of entry into mitosis as the check-
point is relieved. Recently, Venkitaraman and coworkers identi-
fied a role for ubiquitin ligase function of BRCA1 in the activation
of Chk1 after treatment with topoisomerase poisons but not with
mitomycin C (40). Although our data indicate that BRCA1 might
be required to maintain Chk1 activation in response to DNA
cross-link damage, we have observed no dependence on the E3
function of BRCA1 (data not shown).
In cells treated with the replication inhibitor aphidicolin, Chk1
is required to maintain viable replication structures, and it is the
persistence of these structures, rather than Chk1 activation per se,
which maintains the checkpoint until replication is complete (41).
Our data are consistent with a similar model in the repair of DNA
cross-link damage, where stalled forks induced by DNA cross-
linking damage are stabilized and maintained by Chk1, pending
their repair by the FA pathway. Failure to repair these structures
eventually leads to their degeneration and subsequent loss of
checkpoint signal (41). In this model, defects in BRCA1 might
provide a link between preservation of stalled replication forks
and their ability to restart replication after DNA damage. Lack of
BRCA1 might lead to the premature degeneration of stalled rep-
lication structures, the loss of Chk1 signaling, and aberrant entry
into mitosis.
This is supported by work from Ceccaldi et al. (42), who de-
scribed a group of FA patients with attenuated phenotype. Cells
from attenuated FA patients exhibit characteristics very similar to
those reported here for Fancc Brca1/ DT40 mutants (42). Al-
though these patients had nearly normal blood counts, their pe-
ripheral blood lymphocytes failed to arrest in G2 phase after treat-
ment with mitomycin C. Their cells also exhibited numerous
chromosomal breaks. Although the levels of pChk1(ser345) were
not quantified in these patients, they did exhibit lower than nor-
mal levels of Chk1. Importantly, the defective G2 checkpoint
linked to cellular proliferation with increased genome stability
observed in patients’ cells directly mirrors our findings with FA-
defective DT40 cells lacking BRCA1. Ceccaldi et al. suggested that
the enhanced genome instability observed in attenuated FA pa-
tients might contribute to the subsequent development of leuke-
mia in these patients.
Recently, Bunting et al. showed that Brca1ex11/ex11 53bp1/
cells are proficient in homologous recombination but sensitive to
ICL damage. This indicated that, in addition to its function in HR,
BRCA1 has a role in cross-link repair (9). The authors suggest that
BRCA1 helps to promote the localization of FANCD2 to chroma-
tin at sites of DNA damage. However, it is not clear why failure to
efficiently recruit FANCD2 to sites of DNA damage would not also
impact on downstream homologous recombination events. Our
data provide another explanation by showing that BRCA1 is re-
quired to maintain G2 arrest in FA cells. This also explains the
reduced levels of FANCD2 nuclear foci observed in BRCA1-de-
fective cells exposed to ICL. Since the relocalization of FANCD2
occurs mainly in the S and G2 phases of the cell cycle, the escape of
BRCA1-defective cells from G2 phase and their progression into
mitosis would reduce in the proportion of cells exhibiting
FANCD2 foci.
BRCA1 interacts with several partner proteins in a cell cycle
dependent manner through its BRCT domains. Of these, we have
identified a role for ABRAXAS in checkpoint signaling in FA-
deficient cells. Like Fancc Brca1/ mutants, Fancc Abra1/
cells exhibit increased cisplatin resistance and failure to maintain
pCHK1(ser345) levels in G2 compared to FANCC-defective cells.
On the other hand, defects in BRIP1 are not linked with these
phenotypes, indicating that components of the BRCA1-A com-
plex but not of the BRCA1-B complex contribute this G2 check-
point function. Future studies will be required to determine
whether BRCA1-A plays a direct or indirect role in the mainte-
nance of Chk1 activation. However, it is noteworthy that both
DT40 and human cells that are defective in ABRAXAS are profi-
cient in homologous recombination. Since Abra1/ cells do not
maintain G2 arrest, we infer that its function in ICL-induced G2
arrest is genetically separable form homologous recombination.
Hence, our observations might provide an explanation for the
homologous recombination-independent function of BRCA1 re-
ported by Bunting et al. and explain how the loss of BRCA1 can
promote the proliferation and survival of FA cells harboring DNA
damage.
Together, our data uncover an important role for BRCA1 in
the FA pathway in DT40 by promoting the maintenance of DNA-
cross-link-induced G2 arrest many hours after exposure to DNA
damage. This function provides quality control for FA cells enter-
ing into mitosis and promotes apoptotic death in cells with per-
sistent unrepaired DNA damage. Moreover, it is clear that im-
paired DNA repair function coupled with loss of G2 checkpoint
function might have clinical implications for the treatment of at-
tenuated FA patients.
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